Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 
138 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Libtayo (cemiplimab-rwlc) / Regeneron
2021-006372-17: A study to investigate the clinical and immunological effects on field cancerization in patients treated with PD-1 inhibition for advanced or metastatic cutaneous squamous cell carcinoma

Not yet recruiting
4
20
Europe
Cemiplimab, Concentrate and solvent for solution for infusion, LIBTAYO®
Muehlenkreiskliniken AoeR, Sanofi-Aventis
advanced or metastatic cutaneous squamous cell carcinoma, Advanced squamous cell carcinoma of the skin, Diseases [C] - Cancer [C04]
 
 
EMPOWER-Cervical 1, NCT03257267 / 2017-000350-19: Study of Cemiplimab in Adults With Cervical Cancer

Checkmark Post-hoc exploratory analysis of P3 EMPOWER-Cervical 1 trial in advanced cervical cancer at ESMO-IO 2022
Oct 2022 - Oct 2022: Post-hoc exploratory analysis of P3 EMPOWER-Cervical 1 trial in advanced cervical cancer at ESMO-IO 2022
Checkmark Data from P3 EMPOWER-Cervical 1 trial in recurrent or metastatic cervical cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from P3 EMPOWER-Cervical 1 trial in recurrent or metastatic cervical cancer at ESMO 2022
Checkmark Data from trial for 2L cervical cancer
More
Completed
3
608
Europe, Canada, Japan, US, RoW
Cemiplimab, REGN2810, Libtayo, Investigator Choice (IC) Chemotherapy
Regeneron Pharmaceuticals, Sanofi
Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
03/21
04/23
EMPOWER-Lung 3, NCT03409614 / 2017-001311-36: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Checkmark Post-hoc exploratory analysis of P3 EMPOWER-Lung 3 trial in advanced NSCLC at ESMO-IO 2022
Oct 2022 - Oct 2022: Post-hoc exploratory analysis of P3 EMPOWER-Lung 3 trial in advanced NSCLC at ESMO-IO 2022
Checkmark From trial for NSCLC
Sep 2021 - Sep 2021: From trial for NSCLC
Checkmark OS and PFS data from trial for NSCLC at ESMO 2021
More
Active, not recruiting
3
790
Europe, US, RoW
REGN2810, cemiplimab, REGN2810/chemo/ipi, Chemotherapy, Placebo
Regeneron Pharmaceuticals, Sanofi
Non-small Cell Lung Cancer
02/25
02/25
EMPOWER-lung 1, NCT03088540 / 2016-004407-31: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Checkmark OS and PFS data for advanced or metastatic 1L NSCLC
Jul 2021 - Jul 2021: OS and PFS data for advanced or metastatic 1L NSCLC
Checkmark Approval in US for 1L NSCLC
Feb 2021 - Feb 2021: Approval in US for 1L NSCLC
Checkmark Data from study for advanced or metastatic PD L1+ve 1L NSCLC
More
Active, not recruiting
3
712
Europe, RoW
Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
06/25
06/25
NCT06246916: A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Not yet recruiting
3
560
NA
fianlimab, REGN3767, cemiplimab, REGN2810, LIBTAYO®, relatlimab+nivolumab, Opdualag™
Regeneron Pharmaceuticals
Melanoma
03/27
06/33
C-POST, NCT03969004 / 2019-000566-38: Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Calendar Jan 2024 - Dec 2025: Data from trial for adjuvant CSCC
Recruiting
3
412
Europe, Canada, Japan, US, RoW
Cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals, Sanofi
Cutaneous Squamous Cell Carcinoma
05/26
01/28
R3767-ONC-2011, NCT05352672 / 2021-004453-23: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Calendar Jan 2024 - Dec 2025: Data from trial in combination with fianlimab for 1L advanced melanoma
Calendar Jan 2024 - Dec 2025: Data from trial in combination with Fianlimab for advanced melanoma
Hourglass Jun 2022 - Dec 2022 : Updated data from trial for advanced melanoma
Recruiting
3
1590
Europe, Canada, US, RoW
Fianlimab, REGN3767, Cemiplimab, REGN2810, Libtayo, Pembrolizumab, MK-3475, lambrolizumab, Keytruda, Placebo
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc
Melanoma
03/26
08/32
NCT04157985: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Recruiting
3
578
US
Continue PD-1/PD-L1 Inhibitors treatment, Keytruda (pembrolizumab), Optiva (nivolumab), Tecentriq (atezolizumab), Yervoy (ipilimumab), LIBTAYO (cemiplimab), Discontinue PD-1/PD-L1-1 inhibitor
Jason J. Luke, MD
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
10/28
10/28
NCT05608291: A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Recruiting
3
1530
Europe, Canada, US, RoW
Fianlimab, REGN3767, Cemiplimab, REGN2810, Libtayo, Pembrolizumab, MK-3475, lambrolizumab, Keytruda, Placebo
Regeneron Pharmaceuticals
Melanoma
05/28
02/30
R3767-ONC-2208, NCT06190951: A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Not yet recruiting
2/3
520
NA
pembrolizumab, MK-3475, lambrolizumab, Keytruda, Anti-PD1, fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, cemiplimab+fianlimab
Regeneron Pharmaceuticals
Melanoma
09/28
06/33
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2/3
850
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals
Advanced Non-Small Cell Lung Cancer
03/30
02/32
2019-003007-35: Study of Cemiplimab in Patients with type of skin cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Not yet recruiting
2
76
Europe
cemiplimab, REGN2810, Solution for infusion, Libtayo
Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
Stage II to IV cutaneous squamous cell carcinoma, Type of skin cancer Stage II to IV cutaneous squamous cell carcinoma, Diseases [C] - Cancer [C04]
 
 
2018-003964-30: A study evaluating the clinical benefit of Cemiplimab versus Cemiplimab in combination with RP1 in patients with skin cancer

Not yet recruiting
2
240
Europe, RoW
RP1, LIBTAYO, RP1, Solution for injection, Concentrate for solution for infusion, LIBTAYO
Replimune, Inc., Replimune, Inc, Replimune, Inc.
Advanced Cutaneous Squamous Cell Carcinoma, Advanced skin cancer, Diseases [C] - Cancer [C04]
 
 
2020-003652-32: An experimental study in men and women with head and neck cancer to test the efficacy, safety and tolerability of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activates part of the immune system

Not yet recruiting
2
86
Europe, RoW
Human Papilloma Virus (HPV) type 16 E6/E7 synthetic long peptide (SLP®) vaccine, Cemiplimab, ISA101b, REGN2810, Powder and solvent for suspension for injection, Concentrate for solution for infusion, LIBTAYO
ISA Therapeutics B.V., ISA Therapeutics B.V.
Recurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC), Head and neck cancer with human papilloma virus type 16 infection, Diseases [C] - Cancer [C04]
 
 
2020-002195-12: A study to investigate novel agent BNT111 and cemiplimab in combination or as single agents in patients with late stage skin cancer that has not responded to other forms of treatment.

Not yet recruiting
2
180
Europe
BNT111, cemiplimab, BNT111, REGN2810, Concentrate for dispersion for injection, Concentrate for solution for infusion, Libtayo
BioNTech SE, BioNTech SE
Anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma, Advanced black skin cancer that is resistant to approved therapies, Diseases [C] - Cancer [C04]
 
 
R2810-ONC-1620, NCT03132636 / 2016-003122-16: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Checkmark From P2 trial in patients with advanced basal cell carcinoma at ESMO 2020
Sep 2020 - Sep 2020: From P2 trial in patients with advanced basal cell carcinoma at ESMO 2020
Checkmark ORR data from trial for basal cell carcinoma
Sep 2020 - Sep 2020: ORR data from trial for basal cell carcinoma
Checkmark From trial in advanced basal cell carcinoma
More
Completed
2
138
Europe, Canada, US
cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Carcinoma, Basal Cell
05/21
04/23
2021-003266-13: COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2)

Not yet recruiting
2
33
Europe
Keytruda, Libtayo - Cemiplimab, Injection/infusion, Pembrolizumab (KEytruda), Atezolizumab (Tecentriq), Nivolumab (Opdivio), Libtayo (Cemiplimab)
Oslo University Hospital, Oslo university Hospital
Non small cell lung cancer, stage IVPatients are eligible if when they are planned to start immunotherapy according to standard routines and are not in need of radiotherapy, Non small cell lung cancer with extensive disease (metastases) and when immunotherapy is planned to start, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2020-005465-13: Cemiplimab treatment in patients with locally advanced or metastatic blood vessel cancer (angiosarcoma) Onderzoek naar de behandeling met cemiplimab bij patiënten met een lokaal vergevorderde en uitgezaaide kwaadaardige bloedvattumor (angiosarcoom)

Ongoing
2
18
Europe
Cemiplimab, L01XC33, Infusion, LIBTAYO
Radboudumc, Radboudumc, Genzyme Europe B.V.
Patients with locally advanced and metastatic secondary angiosarcomas Patiënten met lokaal vergevorderde en gemetastaseerde secundaire angiosarcomen, Patients with al locally advanced or metastatic blood vessel cancer (secundary angiosarcoma) Patiënten met een lokaal vergevorderde en uitgezaaide kwaadaardige bloedvattumor (angiosarcoom), Diseases [C] - Cancer [C04]
 
 
2020-004052-15: ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with or without platinum-based chemotherapy

Not yet recruiting
2
38
Europe
89Zr-DFO-REGN3767, Libtayo, Solution for injection, Concentrate for concentrate for solution for infusion, Libtayo
University Medical Center Groningen, Regeneron Pharmaceuticals, Inc.
Patients with metastatic solid tumors, where clinical data has shown a rationale for ICI therapy with or without platinum-based chemotherapy, will be included in this study., metastatic solid tumors, Diseases [C] - Cancer [C04]
 
 
NCT04154943: Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Checkmark Presentation of P2 data for neoadjuvant cutaneous squamous cell carcinoma at ESMO 2022
Sep 2022 - Sep 2022: Presentation of P2 data for neoadjuvant cutaneous squamous cell carcinoma at ESMO 2022
Checkmark Data from trial for stage II to IV cutaneous squamous cell carcinoma at ESMO 2022
Sep 2022 - Sep 2022: Data from trial for stage II to IV cutaneous squamous cell carcinoma at ESMO 2022
Active, not recruiting
2
79
Europe, US, RoW
Cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Cutaneous Squamous Cell Carcinoma
12/21
09/25
2021-005136-34: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting
2
188
Europe
THIO, Libtayo (Cemiplimab), THIO, Concentrate for solution for infusion, Libtayo
MAIA Biotechnology, Inc., MAIA Biotechnology, Inc.
Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NEO-CESQ, NCT04632433 / 2019-001469-34: Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Active, not recruiting
2
25
Europe
Cemiplimab
Fondazione Melanoma Onlus
Cutaneous Squamous Cell Carcinoma
02/23
02/26
NCT04177810: Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Completed
2
25
US
Cemiplimab, REGN-2810, LIBTAYO, Plerixafor, AMD3100, MOZOBIL
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genzyme, a Sanofi Company, American Association for Cancer Research, National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
03/23
05/23
ICING, NCT04763616: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Recruiting
2
37
RoW
Isatuximab, Cemiplimab
Won Seog Kim, Sanofi
Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma
04/23
04/26
NCT04646005 / 2020-001239-29: Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Active, not recruiting
2
113
Europe, US, RoW
Cemiplimab, REGN2810, Libtayo, ISA101b
Regeneron Pharmaceuticals, ISA Pharmaceuticals B.V.
Cervical Cancer
05/23
10/24
NCT05535023: Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Withdrawn
2
26
US
SAR444245, Cemiplimab
M.D. Anderson Cancer Center, Sanofi
Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer
07/23
07/23
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
EMPOWER-CSCC-1 , NCT02760498 / 2016-000105-36: Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Checkmark Post-hoc exploratory analysis from trial for cutaneous squamous cell carcinoma at ASCO 2020
May 2020 - May 2020: Post-hoc exploratory analysis from trial for cutaneous squamous cell carcinoma at ASCO 2020
Checkmark Three-year followup data from a trial for cutaneous squamous cell carcinoma at ASCO 2020
May 2020 - May 2020: Three-year followup data from a trial for cutaneous squamous cell carcinoma at ASCO 2020
Checkmark 12 month follow-up data from group 1 of P2 trial at ASCO 2019 [screenshot]
More
Completed
2
432
Europe, US, RoW
cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals
Advanced Cutaneous Squamous Cell Carcinoma
10/23
10/23
ProcemISA, NCT04398524: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
NCT04243616: Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

Recruiting
2
36
US
Cemiplimab, Libtayo, Paclitaxel, Taxol, Abraxane, Carboplatin (not mandatory), Paraplatin, Doxorubicin, Lipodox, Lipodox 50, Doxil, Cyclophosphamide, cytophosphane, Cytoxan, Neosar
Medical College of Wisconsin
Invasive Breast Cancer
01/25
01/26
PRIME-CUT, NCT03951831: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Active, not recruiting
2
20
US
REGN2810, Cemiplimab, Degarelix, Firmagon, Leuprolide Acetate, Lupron, Docetaxel, Taxotere
Mark Stein, Regeneron Pharmaceuticals
Prostate Cancer Metastatic
03/24
04/28
NCT04291105: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
12/24
03/25
RAD-IO, NCT05401786: Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC

Recruiting
2
54
Europe
Ipilimumab, Cemiplimab, SBRT
The Netherlands Cancer Institute, Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
05/24
12/25
NCT05429866: Immunological Variables Associated to ICI Toxicity in Cancer Patients

Recruiting
2
441
Europe
Checkpoint Blockade, Immune, Ipililumab, Nivolumab, Pembrozilumab, atezolizumab, avelumab, durvalumab, Cemiplimab
Jules Bordet Institute
Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Mesothelioma, Malignant, Bladder Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, MSI-H Colorectal Cancer
06/24
12/24
NCT05929664: Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Recruiting
2
35
US
Cemiplimab, 1801342-60-8, Cemiplimab RWLC, Cemiplimab-rwlc, Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer, Libtayo, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized Tomography, CT, CT SCAN, tomography, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI, Biopsy, BIOPSY_TYPE, Bx
Thomas Jefferson University
Locally Advanced Basal Cell Carcinoma
06/24
06/24
THIO-101, NCT05208944: THIO Sequenced With Cemiplimab in Advanced NSCLC

Recruiting
2
182
Europe, RoW
6-Thio-2'-Deoxyguanosine, 6-thio-dG, THIO, Cemiplimab, LIBTAYO®
Maia Biotechnology
Carcinoma, Non-Small-Cell Lung
06/24
12/24
NCT06161441: A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Recruiting
2
180
US
Fianlimab, REGN3767, Cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Taxol, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Resectable Non-small Cell Lung Cancer
09/25
04/29
NCT06205836: Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Recruiting
2
22
US
Cemiplimab, REGN2810, LIBTAYO, Fianlimab, REGN3767
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Regeneron Pharmaceuticals
Colorectal Cancer
05/28
05/28
NCT04315701: A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Recruiting
2
34
US
Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810, Resection, Surgical Resection
University of Southern California, National Cancer Institute (NCI)
Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer, Stage III Skin Cancer
06/24
06/25
NCT04238624: Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Recruiting
2
15
US
Dabrafenib, Trametinib
Memorial Sloan Kettering Cancer Center
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
06/24
06/24
CEMangio, NCT04873375: Cemiplimab for Secondary Angiosarcomas

Recruiting
2
18
Europe
Cemiplimab, LIBTAYO
Radboud University, Genzyme Europe B.V.
Secondary Angiosarcoma, Locally Advanced Sarcoma, Metastasis
07/24
10/25
NCT06385262: TOP 2301: Neoadjuvant Chemo for NSCLC

Not yet recruiting
2
126
NA
Alirocumab, Cemiplimab, Chemotherapy
Duke University, Regeneron Pharmaceuticals
Non Small Cell Lung Cancer
06/26
06/28
VIRO-25, NCT06463665: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Not yet recruiting
2
142
NA
Olvimulogene nanivacirepvec, Olvi-Vec, GL-ONC, GLV-1h68, Platinum chemotherapy: carboplatin or cisplatin, Brand of drug is based on institutional procurement, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Genelux Corporation, Newsoara Biopharma Co., Ltd.
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
02/27
07/29
NCT05967884: PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Not yet recruiting
2
20
Canada
Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
Ottawa Hospital Research Institute, Ontario Institute for Cancer Research
Breast Cancer
08/24
08/24
NEOPECS, NCT06418724: Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Not yet recruiting
2
27
NA
Cetuximab, Erbitux, Cemiplimab, Libtayo
Melanoma and Skin Cancer Trials Limited
Locally Advanced Cutaneous Squamous Cell Carcinoma
01/26
11/27
NCT06465329: A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting
2
120
NA
Cemiplimab, REGN2810, LIBTAYO, Platinum-based chemotherapy, REGN7075, EGFRxCD28 bispecific immunotherapy
Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
06/27
05/30
NEO-SURG, NCT06449313: Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Not yet recruiting
2
21
US
Cemiplimab-Rwlc, Libtayo
Georgetown University, Regeneron Pharmaceuticals
Non-small Cell Lung Cancer Stage III
12/27
09/32
ICARS, NCT06219317: Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

Not yet recruiting
2
136
NA
Cemiplimab, Placebo
European Organisation for Research and Treatment of Cancer - EORTC
NSCLC Stage IV
01/30
01/30
MINIMA, NCT04988074: Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Recruiting
2
32
US
Cemiplimab, LIBTAYO
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Regeneron Pharmaceuticals
HPV-Related Squamous Cell Carcinoma
11/24
08/26
NCT06384820: Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Not yet recruiting
2
140
NA
cemiplimab, REGN2810, Libtayo, fianlimab, REGN3767
Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma
06/26
05/30
NCT06448026: A Phase 2 Study to Evaluate the Efficacy of the Combination of Cemiplimab and Cetuximab Prior to Salvage Surgery in Patients With Locally Recurrent (Stage 3-5) OCSCC

Not yet recruiting
2
17
US
Cemiplimab, Cetuximab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals
Locally Recurrent OCSCC
05/25
05/27
NCT06444880: Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Not yet recruiting
2
40
US
Ubamatamab, Cemiplimab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals
SMARCB1-Deficient Malignancies
07/26
07/28
NCT04679480: Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Recruiting
2
20
Europe
Cemiplimab Injection [Libtayo], Sonidegib
Reinhard Dummer, Sanofi, Sun Pharmaceutical Industries Ltd
Basal Cell Carcinoma
12/24
12/24
NCI-2018-01313, NCT03565783: Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Checkmark From P2 trial in head and neck squamous cell cancer at ESMO 2019 [screenshot]
Sep 2019 - Sep 2019: From P2 trial in head and neck squamous cell cancer at ESMO 2019 [screenshot]
Recruiting
2
40
US
Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
12/24
12/24
NCT04862650: Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
42
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
Marcelo Bonomi
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Lip and Oral Cavity Cancer AJCC v8
12/24
12/24
NCT03916627: Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Checkmark Results for resectable HCC
Apr 2021 - Apr 2021: Results for resectable HCC
Recruiting
2
73
US
cemiplimab, REGN2810, Libtayo, Platinum Doublet, fianlimab, REGN3767
Regeneron Pharmaceuticals, Sanofi
Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
04/25
02/31
NCT05961709: The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Recruiting
2
50
US
Cemiplimab
M.D. Anderson Cancer Center, Regeneron Pharmaceuticals
Colon Cancer
04/26
04/28
Chemo4METPANC, NCT04543071: Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Recruiting
2
10
US
Motixafortide, BL-8040, Cemiplimab, REGN2810, Gemcitabine, Gemzar, Nab paclitaxel, Abraxane
Gulam Manji, Regeneron Pharmaceuticals, BioLine Rx
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
07/25
08/25
LUNGVAC, NCT05344209: Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

Recruiting
2
138
Europe
UV1, Sagramostim, leukine, Anti-PD-1/PD-L1 treatment
Vestre Viken Hospital Trust, University Hospital, Akershus, Oslo University Hospital, Haukeland University Hospital, Helse Stavanger HF, Helse Fonna, Helse Nord-Trøndelag HF, St. Olavs Hospital, Alesund Hospital, Helse Forde, University Hospital of North Norway
Oncology, NSCLC Stage IV, NSCLC, Stage III
07/25
07/27
CERPASS, NCT04050436: Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Hourglass Jul 2023 - Sep 2023 : Topline data from CERPASS trial in combination with RP1 for advanced CSCC
Active, not recruiting
2
231
Europe, Canada, US, RoW
Cemiplimab, Libtayo, RP1, Genetically modified herpes simplex type 1 virus
Replimune Inc., Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
09/25
09/25
NCT04526899: Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Active, not recruiting
2
184
Europe, US, RoW
BNT111, Cemiplimab
BioNTech SE, Regeneron Pharmaceuticals
Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
11/25
07/26
NCT05669989: International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Recruiting
2
70
Europe, Japan, US, RoW
Isatuximab intravenous (IV), SARCLISA®, SAR650984, Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Sanofi
Plasma Cell Myeloma
11/26
11/26
NCT05574101: A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Recruiting
2
34
US
Cemiplimab, Radiotherapy
Memorial Sloan Kettering Cancer Center
Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma of the Skin, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma
10/26
10/26
NCT05553834: PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Recruiting
2
60
US
Alirocumab and Cemiplimab
Duke University, Regeneron Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
01/27
01/29
NCT05557591: A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Recruiting
2
100
Europe, US, RoW
BNT116, Cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, BioNTech SE
Advanced Non-Small Cell Lung Cancer
03/27
06/27
NCT04916002: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Suspended
2
225
US, RoW
vidutolimod, CMP-001, cemiplimab, Libtayo, REGN2810
Regeneron Pharmaceuticals
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
07/27
07/27
NCT05694871: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Recruiting
2
72
US
Palbociclib, PD-0332991, Cemiplimab, Cemiplimab RWLC, Immunoglobulin G4, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
05/27
05/27
NCT05840770: Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Recruiting
2
34
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cemiplimab, Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN2810, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Elastography, MRE, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
10/29
10/29
DISCERN, NCT05878288: Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Recruiting
2
10
RoW
Cemiplimab, Libtayo, REGN-2810, REGN2810, cemiplimab-rwlc
Peter MacCallum Cancer Centre, Australia, University of Melbourne, University of Adelaide, Monash University, Regeneron Pharmaceuticals, Sanofi
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin Cancer
05/29
05/29
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Metastatic Uveal Melanoma
10/30
10/30
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
JX594-REN026, NCT03294083: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting
1b/2a
89
US, RoW
Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab
SillaJen, Inc., Regeneron Pharmaceuticals
Renal Cell Carcinoma
08/23
11/23
2019-003298-24: A study to examine REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer

Not yet recruiting
1/2
554
Europe
Libtayo, REGN4018, REGN2810, Concentrate for solution for infusion, Powder for solution for infusion, Powder for solution for injection, Libtayo
Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
Recurrent Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal Cancer, Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer, Diseases [C] - Cancer [C04]
 
 
2020-005332-30: A study of SAR444245 combined with cemiplimab for the treatment of participants with various advanced skin cancers Studio di SAR444245 in combinazione con cemiplimab per il trattamento di pazienti con vari tumori cutanei in stadio avanzato

Not yet recruiting
1/2
100
Europe
NA, cemiplimab, [SAR444245], [REGN2810], Concentrate for solution for infusion
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi Aventis Recherche & Développement
Advanced unresectable or metastatic skin cancers Tumori cutanei non resecabili o metastatici in stadio avanzato, Skin Cancer Tumore cutaneo, Diseases [C] - Cancer [C04]
 
 
2022-002234-14: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies

Ongoing
1/2
140
Europe
OR2805, Libtayo, OR2805, Infusion, Libtayo / Cemiplimab
OncoResponse, Inc., OncoResponse, Inc.
Solid tumor cancer, Cancer/ solid tumors, Diseases [C] - Cancer [C04]
 
 
CONTRAC, NCT04339062: Cemiplimab in AlloSCT/SOT Recipients With CSCC

Active, not recruiting
1/2
12
US
Cemiplimab, Libtayo, Everolimus, Afinitor, Zortress, Sirolimus, Rapamune, Prednisone, Deltasone, Prednicot, predniSONE Intensol, Rayos, Sterapred, Sterapred DS
Dana-Farber Cancer Institute, Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
06/23
01/25
NCT03194867 / 2017-001431-39: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Hourglass Jan 2021 - Dec 2021 : From trial in combination with isatuximab for r/r multiple myeloma
Hourglass Jan 2020 - Dec 2020 : OS secondary analysis data from trial in combination with isatuximab for r/r multiple myeloma
Completed
1/2
109
Europe, Canada, US, RoW
Isatuximab SAR650984, Sarclisa, Cemiplimab REGN2810
Sanofi
Plasma Cell Myeloma
04/23
04/23
NCT03690869 / 2023-000604-19: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Calendar Jan 2025 - Dec 2025: From trial n pediatrics with solid tumors
Terminated
1/2
57
US
cemiplimab (monotherapy), REGN2810, Libtayo, cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Regeneron Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
05/23
05/23
NCT04913220: A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Active, not recruiting
1/2
46
Europe, US, RoW
THOR-707, Cemiplimab, Libtayo® or generic
Sanofi
Malignant Melanoma, Squamous Cell Carcinoma of Skin
08/23
02/25
NCT03491683: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Checkmark From trial in combination with INO-5401 & INO-9012 for 1L GBM
Nov 2019 - Nov 2019: From trial in combination with INO-5401 & INO-9012 for 1L GBM
Active, not recruiting
1/2
52
US
INO-5401, INO-9012, Cemiplimab, REGN2810, Radiation Therapy, Temozolomide
Inovio Pharmaceuticals
Glioblastoma
12/24
12/24
PRO-MERIT, NCT04382898 / 2018-004321-86: (Prostate Cancer Messenger RNA Immunotherapy)

Terminated
1/2
75
Europe, US
BNT112, Cemiplimab
BioNTech SE
Prostate Cancer
01/24
01/24
BIOSELECT, NCT05538988: BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

Not yet recruiting
1/2
16
Canada
Cemiplimab, Libtayo
AHS Cancer Control Alberta
Mycosis Fungoides
02/25
03/26
NCT05094804 / 2022-002234-14: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Recruiting
1/2
172
US
OR2805, Cemiplimab, Libtayo, Docetaxel, Taxotere
OncoResponse, Inc., OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
04/24
08/24
NCT04305795: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Active, not recruiting
1/2
74
US
200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929
Rakuten Medical, Inc.
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
06/24
06/25
NCT06162572: Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Not yet recruiting
1/2
176
US, RoW
S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE, S095029 RDE, Cemiplimab
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier, Regeneron Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
04/27
07/27
R4018-ONC-1721, NCT03564340: Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Hourglass Oct 2023 - Oct 2023 : Data from a P1 portion of the trial in combination with ubamatamab for recurrent ovarian cancer at ESMO 2023
Checkmark Data from a trial in combination with REGN4018 for ovarian cancer at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from a trial in combination with REGN4018 for ovarian cancer at ESMO-IO 2022
Recruiting
1/2
690
Europe, US, RoW
REGN4018, Ubamatamab®, cemiplimab, REGN2810, Sarilumab
Regeneron Pharmaceuticals
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
06/26
06/26
NCT04706715: LAG3 PET Imaging in Advanced Solid Tumors

Active, not recruiting
1/2
41
Europe
89Zr-DFO-REGN3767, Cemiplimab
University Medical Center Groningen, Regeneron Pharmaceuticals
Metastatic Solid Tumor
09/24
09/24
NCT06412198: A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Not yet recruiting
1/2
31
US
Cetuximab, ERBITUX, Cemiplimab, Adagrasib
M.D. Anderson Cancer Center
Metastatic Colorectal Cancer, KRAS G12C Mutations
03/26
03/28
NCT04989946: Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Recruiting
1/2
60
US
Degarelix, pTVG-AR, Nivolumab, Opdivo, Cemiplimab, Libtavo, Fianlimab, REGN3767, FLT PET/CT, 3'-Deoxy-3'-[18F]Fluorothymidine (FLT) positron emission tomography (PET) /computed tomography (CT)
University of Wisconsin, Madison, Madison Vaccines, Inc, United States Department of Defense, Regeneron Pharmaceuticals, Bristol-Myers Squibb, National Cancer Institute (NCI)
Prostate Cancer
12/26
12/28
GLIMMER-01, NCT05259696: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein

Recruiting
1/2
273
US
E-602, Cemiplimab, Libtayo, REGN2810
Palleon Pharmaceuticals, Inc.
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
06/25
06/25
NCT03972657: A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Recruiting
1/2
345
US
REGN5678, Cemiplimab, REGN2810, LIBTAYO
Regeneron Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
08/25
07/26
NCT05662397: A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Recruiting
1/2
203
US
HST-1011, CBL-B inhibitor, Cemiplimab, anti-PD1 antibody
HotSpot Therapeutics, Inc
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
12/25
12/26
NCT04954599: Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Recruiting
1/2
126
Europe
CP-506, HAP CP-506, Carboplatin, Paraplatin, Immune checkpoint inhibitor, Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Cemiplimab
Maastricht University Medical Center, Erasmus Medical Center, Jules Bordet Institute, Academisch Ziekenhuis Maastricht
Unspecified Adult Solid Tumor, Protocol Specific
02/26
05/26
NCT05501665: Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Suspended
1/2
25
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Varian Medical Systems
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
02/26
02/27
NCT06090266: A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Recruiting
1/2
168
US
OR502, Cemiplimab
OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Platinum-resistant Ovarian Cancer, Cutaneous Squamous Cell Carcinoma
08/26
02/27
NCT05125016: A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Recruiting
1/2
370
US
REGN4336, Cemiplimab, REGN2810, REGN5678, Sarilumab, REGN88, SAR153191
Regeneron Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
01/27
01/27
COMBINE-EGFR-1, NCT04626635: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Recruiting
1/2
769
Europe, US, RoW
REGN7075, cemiplimab, REGN2810, Libtayo, Platinum-based doublet chemotherapy
Regeneron Pharmaceuticals
Advanced Solid Tumors
08/26
12/26
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Recruiting
1/2
180
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
08/26
09/26
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Recruiting
1/2
237
US
REGN5093-M114, Cemiplimab
Regeneron Pharmaceuticals
Advanced NSCLC
02/30
02/30
 

Download Options